EX-99.1
2
a6076404ex99_1.htm
EXHIBIT 99.1
Exhibit 99.1
Pfizer
Completes Acquisition Of Wyeth
NEW YORK--(BUSINESS WIRE)--October 15, 2009--Pfizer (NYSE: PFE) and
Wyeth (NYSE: WYE) announced today that Pfizer has completed its
acquisition of Wyeth following the receipt of regulatory approval from
all government authorities required by the merger agreement and approval
by Wyeth shareholders. Under the terms of the transaction, each
outstanding share of Wyeth common stock has been converted into the
right to receive $33 in cash (without interest) and 0.985 of a share of
Pfizer common stock.
Effective as of the close of trading today, October 15, 2009, Wyeth
common stock (NYSE: WYE) will cease trading.
Pfizer and Wyeth will begin joint operations tomorrow, October 16, 2009.
The merger of local Pfizer and Wyeth entities may be pending in various
jurisdictions and integration is subject to completion of various local
legal and regulatory obligations.
Pfizer has appointed Computershare Trust Company as exchange agent and
paying agent in connection with the merger. Wyeth registered
shareholders with questions regarding payment for Wyeth common stock
should contact Computershare Trust Company at (877) 745-9320 and outside
the U.S., Canada and Puerto Rico at +1 (781)575-4336. Additional
information will also be mailed to Wyeth registered shareholders. Wyeth
shareholders who hold stock through a broker or bank should receive
information regarding the conversion of their shares from the party
holding their shares.
Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health
and well-being at every stage of life. We strive to set the standard for
quality, safety and value in the discovery, development and
manufacturing of medicines for people and animals. Our diversified
global health care portfolio includes human and animal biologic and
small molecule medicines and vaccines, as well as nutritional products
and many of the world's best-known consumer products. Every day, Pfizer
colleagues work across developed and emerging markets to advance
wellness, prevention, treatments and cures that challenge the most
feared diseases of our time. Consistent with our responsibility as the
world's leading biopharmaceutical company, we also collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, Pfizer has worked to make a difference for all
who rely on us. To learn more about our commitments, please visit us at
www.pfizer.com
Wyeth is now a wholly owned subsidiary of Pfizer Inc. The merger of
local Wyeth and Pfizer entities may be pending in various jurisdictions
and integration is subject to completion of various local legal and
regulatory obligations.
More information is available at
www.pfizer.com
.
Follow Pfizer on
www.Twitter.com/pfizer_news
.
CONTACT:
Pfizer
Media:
Joan Campion, 212-733-2798
Investor:
Suzanne
Harnett, 212-733-8009

EX - 99 . 1 2 a6076404ex99 _ 1 . htm EXHIBIT 99 . 1 Exhibit 99 . 1 Pfizer Completes Acquisition Of Wyeth NEW YORK -- ( BUSINESS WIRE ) -- October 15 , 2009 -- Pfizer ( NYSE : PFE ) and Wyeth ( NYSE : WYE ) announced today that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders . Under the terms of the transaction , each outstanding share of Wyeth common stock has been converted into the right to receive $ 33 in cash ( without interest ) and 0 . 985 of a share of Pfizer common stock . Effective as of the close of trading today , October 15 , 2009 , Wyeth common stock ( NYSE : WYE ) will cease trading . Pfizer and Wyeth will begin joint operations tomorrow , October 16 , 2009 . The merger of local Pfizer and Wyeth entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory obligations . Pfizer has appointed Computershare Trust Company as exchange agent and paying agent in connection with the merger . Wyeth registered shareholders with questions regarding payment for Wyeth common stock should contact Computershare Trust Company at ( 877 ) 745 - 9320 and outside the U . S . , Canada and Puerto Rico at + 1 ( 781 ) 575 - 4336 . Additional information will also be mailed to Wyeth registered shareholders . Wyeth shareholders who hold stock through a broker or bank should receive information regarding the conversion of their shares from the party holding their shares . Pfizer Inc : Working together for a healthier world ™ At Pfizer , we apply science and our global resources to improve health and well - being at every stage of life . We strive to set the standard for quality , safety and value in the discovery , development and manufacturing of medicines for people and animals . Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines , as well as nutritional products and many of the world 's best - known consumer products . Every day , Pfizer colleagues work across developed and emerging markets to advance wellness , prevention , treatments and cures that challenge the most feared diseases of our time . Consistent with our responsibility as the world 's leading biopharmaceutical company , we also collaborate with health care providers , governments and local communities to support and expand access to reliable , affordable health care around the world . For more than 150 years , Pfizer has worked to make a difference for all who rely on us . To learn more about our commitments , please visit us at www.pfizer.com Wyeth is now a wholly owned subsidiary of Pfizer Inc . The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory obligations . More information is available at www.pfizer.com . Follow Pfizer on www.Twitter.com/pfizer_news . CONTACT : Pfizer Media : Joan Campion , 212 - 733 - 2798 Investor : Suzanne Harnett , 212 - 733 - 8009